Organization
Pharnext
2 clinical trials
Clinical trial
International, Multi-center, Open Label, Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1AStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)Status: Active (not recruiting), Estimated PCD: 2024-04-19